pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma
Ningbo Cancer Hospital
Ningbo Cancer Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Muscle-invasive bladder cancer, Unresectable intrahepatic cholangiocarcinoma, Head and neck squamous cell carci
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 120
- Drugs
- 183
- Patents
- 0
CTRIAL-IE 19-17
Phase 1 · other · Relapsed/ refractory multiple myeloma
CTRIAL-IE 19-17 for Relapsed/ refractory multiple myeloma is a Phase 1 program (other) at Ningbo Cancer Hospital with 1 ClinicalTrials.gov record(s).
Internal code CTRIAL-IE 19-17
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ningbo Cancer Hospital
- Phase
- Phase 1
- Modality
- other
- Indication
- Relapsed/ refractory multiple myeloma
- Status
- active
- Trials
- 1